In conclusion, our findings demonstrate that the infiltration of CD8-positive cells into the tumor, along with the IHC subtype of SCLC, serve as promising prognostic factors for patients with ED-SCLC who receive chemoimmunotherapy as first-line treatment. The gene discussed is CD8A; the disease is small cell lung carcinoma.